Product Profiles: Multiple Sclerosis - Gilenya Raises Bar for New Market Entrants

Description: Introduction

Beginning with the recent approval of Gilenya (Novartis; fingolimod), MS patients are experiencing the arrival of more effective and less invasive treatment options after numerous years of limited therapeutic options. As competition intensifies, the need for less invasive modes of administration will be met and new drugs will have to compete on other factors, such as efficacy.

Features and benefits

- Understand The independent appraisal of marketed brands and key pipeline agents indicated for treating multiple sclerosis.
- Illustrate how pipeline and marketed drugs compare to one another in terms of clinical and commercial attributes.
- Assessment of the strengths, weaknesses, opportunities, and threats for key marketed and pipeline therapies.
- Review of important clinical developments for key pipeline agents with analysis of the latest clinical trial data.
- Determine to what extent current and future therapies satisfy the main clinical unmet needs in multiple sclerosis treatment.

Highlights

The recent survey reveals that US neurologists prescribe Gilenya because of its strong efficacy in treatment resistant patients as well as its convenient oral mode of administration. However, long term cancer and infection risk remain the main concerns.

The multiple sclerosis market has been lucrative for drug companies over the last decade with limited competition and periodic price increases. However, as this dynamic is changing with increased competition, existing players are expanding their portfolios with new and improved therapies. Monoclonal antibodies have demonstrated potent efficacy in Phase II trials, surpassing all existing therapies. However, excitement is tempered with safety concerns that include risk of malignancy and severe infections. Still, as seen with Tysabri, impressive efficacy may outweigh the risks for more severe multiple sclerosis patients.

Your key questions answered

- How well do agents in late-stage development for multiple sclerosis compare to one another and the current standard of care?
- What is the most promising treatment in development for multiple sclerosis?
- How do US neurologists perceive Gilenya and key pipeline agents as new treatments of multiple sclerosis?

Contents:

Executive Summary
- Strategic scoping and focus
- Datamonitor key findings
- Related reports

OVERVIEW
- Catalyst
- Summary

MARKET OVERVIEW
- Product overview
- Datamonitor’s assessment summary

MARKETED PRODUCT PROFILES
- Gilenya (fingolimod; Novartis/Mitsubishi Tanabe Pharma)
- Drug profile
Development overview
SWOT analysis
Satisfaction of unmet needs
Product positioning
Physician perception of Gilenya
Clinical and commercial attractiveness
Avonex (interferon beta-1a; Biogen Idec)
Drug profile
Development overview
SWOT analysis
Satisfaction of unmet needs
Product positioning
Clinical and commercial attractiveness
Rebif (interferon beta-1a; Merck Serono)
Drug profile
Development overview
SWOT analysis
Satisfaction of unmet needs
Product positioning
Clinical and commercial attractiveness
Betaseron (interferon beta-1b; Bayer Schering)
Drug profile
Development overview
SWOT analysis
Satisfaction of unmet needs
Product positioning
Clinical and commercial attractiveness
Extavia (interferon beta-1a; Novartis)
Drug profile
Development overview
SWOT analysis
Satisfaction of unmet needs
Product positioning
Clinical and commercial attractiveness
Copaxone (glatiramer acetate; Teva)
Drug profile
Development overview
SWOT analysis
Satisfaction of unmet needs
Product positioning
Clinical and commercial attractiveness
Tysabri (natalizumab; Biogen Idec/Elan)
Drug profile
Development overview
SWOT analysis
Satisfaction of unmet needs
Product positioning
Clinical and commercial attractiveness
Ampyra (dalfampridine; Acorda Therapeutics/Biogen Idec/Elan)
Drug profile
Development overview
SWOT analysis
Satisfaction of unmet needs
Product positioning
Clinical and commercial attractiveness
Sativex (nabiximols; GW Pharmaceuticals)
Drug profile
Development overview
SWOT analysis
Satisfaction of unmet needs
Product positioning
Clinical and commercial attractiveness
Other marketed drugs for multiple sclerosis
PIEpline Product Profiles

Novantrone (mitoxantrone; Merck Serono)

Movectro (cladribine; Merck Serono)
Drug profile
Development overview
SWOT analysis
Satisfaction of unmet needs
Physician perception of Movectro
Clinical and commercial attractiveness

Monthly Avonex (PEGylated interferon beta-1a; Biogen Idec)
Drug profile
Development overview
SWOT analysis
Satisfaction of unmet needs
Physician perception of monthly Avonex
Clinical and commercial attractiveness

BG-12 (dimethyl fumarate; Biogen Idec)
Drug profile
Development overview
SWOT analysis
Satisfaction of unmet needs
Physician perception of BG-12
Clinical and commercial attractiveness

Laquinimod (Teva)
Drug profile
Development overview
SWOT analysis
Satisfaction of unmet needs
Physician perception of laquinimod
Clinical and commercial attractiveness

Daclizumab (Biogen Idec/Abbott)
Drug profile
Development overview
SWOT analysis
Satisfaction of unmet needs
Physician perception of daclizumab
Clinical and commercial attractiveness

Teriflunomide (HMR1726; Sanofi)
Drug profile
Development overview
SWOT analysis
Satisfaction of unmet needs
Physician perception of teriflunomide
Clinical and commercial attractiveness

Lemtrada (alemtuzumab; Genzyme/Bayer Schering)
Drug profile
Development overview
SWOT analysis
Satisfaction of unmet needs
Physician perception of Lemtrada
Clinical and commercial attractiveness

Ocrelizumab (R15-2477; Roche/Biogen Idec)
Drug profile
Development overview
SWOT analysis
Physician perception of ocrelizumab
Satisfaction of unmet needs
Clinical and commercial attractiveness

Other drugs in development for multiple sclerosis
Tovaxin (Opexa Therapeutics)
BHT-3009 (Bayhill Therapeutics)
Neurovax (Immune Response BioPharma)
Firategrast (GlaxoSmithKline)
ATL1102 (Isis Pharmaceuticals/Antisense Therapeutics)
BAF312 (Novartis)
Ponesimod (R-3477; Actelion)
ONO-4641 (Ono Pharmaceuticals)
Arzerra (ofatumumab; Genmab/GlaxoSmithKline)
LY2127399 (Eli Lilly)
Pleneva (BGC-20-0134; BTG)
IPX056 (baclofen controlled release; Impax Laboratories)
MCT-125 (lofepramine and L-phenylalanine; Multicell Technologies)

BIBLIOGRAPHY
Journal papers
Websites
Other sources
Datamonitor reports

APPENDIX A
Datamonitor drug assessment scorecard
Physician research methodology
Physician sample breakdown
The survey questionnaire

Introduction
Section 1: Unmet Needs
Section 2: Influencing factors on prescribing
Section 3: New therapies entering Multiple Sclerosis
Demographics

APPENDIX B
Market definition
PharmaVitae Explorer database
Contributing experts
Conferences attended
Report methodology

Ordering:
Order Online - http://www.researchandmarkets.com/reports/1841621/
Order by Fax - using the form below
Order by Post - print the order form below and send to
Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Product Profiles: Multiple Sclerosis - Gilenya Raises Bar for New Market Entrants
Web Address: http://www.researchandmarkets.com/reports/1841621/
Office Code: SCD2KD2B

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Quantity</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Hard Copy:</td>
<td>USD 11500 + USD 57 Shipping/Handling</td>
</tr>
<tr>
<td>Electronic (PDF) - Single User:</td>
<td>USD 11400</td>
</tr>
<tr>
<td>Electronic (PDF) - Enterprisewide:</td>
<td>USD 28500</td>
</tr>
</tbody>
</table>

* Shipping/Handling is only charged once per order.

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: Mr [ ] Mrs [ ] Dr [ ] Miss [ ] Ms [ ] Prof [ ]
First Name: ____________________________ Last Name: ____________________________
Email Address: * ____________________________
Job Title: ____________________________
Organisation: ____________________________
Address: ____________________________
City: ____________________________
Postal / Zip Code: ____________________________
Country: ____________________________
Phone Number: ____________________________
Fax Number: ____________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:

<table>
<thead>
<tr>
<th>Account number</th>
<th>833 130 83</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sort code</td>
<td>98-53-30</td>
</tr>
<tr>
<td>Swift code</td>
<td>ULSBIE2D</td>
</tr>
<tr>
<td>IBAN number</td>
<td>IE78ULSB98533083313083</td>
</tr>
<tr>
<td>Bank Address</td>
<td>Ulster Bank, 27-35 Main Street, Blackrock, Co. Dublin, Ireland.</td>
</tr>
</tbody>
</table>

If you have a Marketing Code please enter it below:

Marketing Code:

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World